Tvardi Therapeutics, Inc. (TVRD)

♥ 470 Thanks from members

Tvardi Therapeutics (TVRD) faces a going-concern warning and widening losses, balanced by positive Phase 1 healthy-volunteer results for its next-gen STAT3 inhibitor TTI-109, positioning ulcerative colitis as its initial clinical indication.

Special Briefing

How to Live for 300 Years: The Longevity Sandbox

Explore plasma cleansing, somatic organ swaps, and BCI.

Explore →

Other Nasdaq Tickers

NASDAQ

Microchip Technology Incorporated (MCHP)

NASDAQ

Direxion Daily AAPL Bear 1X ETF (AAPD)

NASDAQ

Ascentage Pharma Group International - American Depository Shares (AAPG)

NASDAQ

Direxion Daily AAPL Bull 2X ETF (AAPU)

NASDAQ

Alpha Blue Capital US Small-Mid Cap Dynamic ETF (ABCS)

NASDAQ

AbCellera Biologics Inc. - Common Shares (ABCL)

Entity & Market Metadata

Sector: Healthcare Industry: Biotechnology / Oncology Founder: Tvardi Therapeutics Scientific Founders Leadership: Imran Alibhai (CEO) Leadership: David Blaha (CFO) Holder: Venture Capital Investors Holder: Institutional Life Science Funds STAT3 Inhibitors Oncology Therapeutics Fibrosis Treatments #TVRD #Tvardi Therapeutics #Biotech Stock #STAT3 Inhibitor #Cancer Research